pitavastatin and Esophageal-Neoplasms

Despite increasing knowledge on oral and esophageal squamous cell carcinoma (OSCC and ESCC), specific medicines against both have not yet been developed. Here, we aimed to find novel anticancer drugs through functional cell-based screening of an FDA-approved drug library against OSCC and ESCC. Pitavastatin, an HMGCR inhibitor, emerged as an anticancer drug that inhibits tumor growth by downregulating AKT and ERK signals in OSCC and ESCC cells. One of the mechanisms by which pitavastatin inhibits cell growth might be the suppression of MET signaling through immature MET due to dysfunction of the Golgi apparatus. Moreover, the sensitivity of tumor growth to pitavastatin might be correlated with

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mice; Mouth Neoplasms; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Triazines; Xenograft Model Antitumor Assays